Better Obesity Drug Race: Novo Nordisk vs Lilly 2026
In the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Identify essential line items for unexpected bills and set aside funds to smooth out financial shocks. A clear plan reduces anxiety and keeps spending in check.
15,931 articlesIn the race to dominate obesity drugs, Novo Nordisk and Eli Lilly are frontrunners. This guide analyzes who has the e...
Roundhill unveiled plans for a suite of ETFs that would track prediction-market odds on the 2028 U.S. election, signa...
A nobel laureate economist warns that anxiety about AI displacing workers risks shaping real outcomes, not just headl...
A loose, little-regulated lending network is stepping in to help small businesses cover tariffs quickly, but with ste...
A Flywire director recently sold 6,524 shares. This guide explains what insider moves mean, how to read Form 4 data, ...
A Phase 3 breakthrough unleashed a dramatic move in Cogent Biosciences. A large fund followed with a sizable stake, s...
Rising AI adoption is outpacing hardware and data-center capacity, forcing cloud providers to ration compute. The bot...
Vale’s shares fell as iron ore demand in China cooled, signaling wider margin pressures for metals. This guide breaks...
A powerful shift is forming: auto plants turning into energy storage hubs to power data centers and grids. This unsto...
A mid-cap tech stock has quietly outperformed NVIDIA on a three-year price-return basis, triggering renewed interest ...
FuelCell Energy leads a morning surge in hydrogen names, delivering outsized gains while peers lag. Analysts point to...
Newmont released after-hours results, signaling steady production yet revenue depends on gold prices. The company gui...